What's new?

The firm manages €2B across its life sciences platform, €1B of which has been raised in the last 4 years

Paris, France – October 17th, 2019 — Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the close of its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its platform of life sciences funds.

Pursuing the strategy it has consistently applied over the years for its flagship early-stage Capital funds, Sofinnova Capital IX will invest in the healthcare industry and more specifically in the biopharmaceutical and medical device sectors. Sofinnova Partners will seek to invest as a founding and lead investor in start-ups and corporate spin-offs, and focus on therapeutic, paradigm-shifting technologies and products alongside visionary entrepreneurs. Sofinnova Capital IX will invest about two thirds of its funds in European companies, and one third outside of Europe, primarily in North America.

The new fund has commitments from leading institutional investors, predominantly endowment funds, insurance companies, pension funds, sovereign funds, corporates and family offices, many of whom are continuing a long and successful relationship with the Sofinnova family of Funds. The majority of commitments came in from Europe, including France, Italy, Ireland, Denmark, Germany, Switzerland, the United Kingdom and Luxembourg, but also from leading North American investors in the U.S. and Canada, as well as major investors from Asia.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said, “Our experienced team, stable strategy and exit track record resonated well with investors, hence the success of our fundraising for this latest Capital fund. Over the last three years, we have completed nine remarkable exits in the portfolio for a total enterprise value of almost 4 billion euros.”

The launch of Sofinnova Capital IX follows the formation, in just the last three years, of Sofinnova Crossover I, a fund investing in pre- and post-IPO companies; Sofinnova MD Start III, a medical device acceleration fund; Sofinnova Industrial Biotech I, a fund dedicated to industrial biotech; and Sofinnova Telethon Fund I, a fund dedicated to seed investments in gene and cell therapies based out of Milan, Italy. With these focused franchises managed by dedicated specialist teams, Sofinnova Partners has established a unique and comprehensive platform of investment vehicles across the life sciences investment value chain.

Triago acted as placement agent and Clifford Chance acted as legal counsel on Sofinnova Capital IX.

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com

Media Contacts:
Kate Barrette
RooneyPartners LLC

Anne Rein
+33 6 03 35 92 05


Diatos SA, a privately held biopharmaceutical company that develops novel therapeutics based on its innovative drug-targeting (TSP) and intracellular-delivery (DPV) technologies, announced today the appointments of Denis Ravel, Ph.D., to the position of Chief R&D Officer, and Sandrine Leonardi to the position of Finance Director. With these appointments Diatos has completed its core management team.

Dr. Ravel brings 18 years of experience in the biotechnology and pharmaceutical industry with extensive background in preclinical and early clinical development of new drugs in the field of metabolic diseases. Prior to joining Diatos, Dr. Ravel was Director of Pharmaceutical Development at Genset and in charge of the Genset San Diego Research Center. In his position at Genset, he led the preclinical development of Famoxin [APM-1], a recombinant protein with anti-diabetic activities. Prior to joining Genset in 2001, Dr Ravel worked for 16 years at Servier, as Senior Pharmacologist and as Project Manager of preclinical and early clinical Drug Development before being promoted to Head of Department. Dr. Ravel obtained a Ph.D. in Biochemistry from Université Pierre et Marie Curie, Paris, France, in 1983.

Sandrine Leonardi joins Diatos from ifrance (a VU group company) where she was Finance Director of the French company and its Spanish subsidiary (iespana). Ms. Leonardi’s prior positions include being Finance Controller Europe of Louis Vuitton Malletier and Head of Financial Control for Europe 2 Communication. Ms. Leonardi graduated from HEC, a leading French Business School, Paris, France, in 1992, and obtained a Masters in Political Science from Columbia University, New-York, USA, in 1993.

"We are pleased to have executives with Denis’s and Sandrine’s experience join our fast-growing company," said Dr John Tchelingerian, President and CEO of Diatos. "Denis’s experience in pharmaceutical development will be extremely valuable as we advance our pipeline of therapeutic products through preclinical and clinical development."

Contacts: Diatos
Dr. John Tchelingerian, President and CEO
Tel: +33 1 53 80 93 81

About Diatos
Diatos is a privately held biopharmaceutical company that uses its proprietary drug-targeting and intracellular-delivery technologies to develop innovative therapies for cancer and other serious diseases. Diatos has two core technology platforms:

Diatos Peptide Vector (DPV) technology enables or significantly enhances selective cellular or nuclear uptake of a broad range of therapeutic compounds, including small molecules, peptides and proteins, antibodies and antibody fragments, oligonucleotides, and nanospheres.

Tumor Selective Prodrug (TSP) technology enables the release of anti-cancer agents selectively at the sites of tumor cells.

In addition to using these technologies to develop its own product pipeline, Diatos is offering these technologies to pharmaceutical and biotechnology companies, under licensing or partnering relationships, for the development of a broad range of therapeutic products in various therapeutic fields and for target validation and drug screening.

Founded in 1999 as a spin-off from Institut Pasteur, Diatos has raised to date 23.5 Million Euros. Diatos has a total of 40 employees at its headquarters in Paris, France, and at the campus of Louvain-la-Neuve Université in Louvain, Belgium.


Over 40 CEOs from Europe and the US came together on the island of Corsica for a trans-Atlantic meeting of the minds

We’re pleased to announce that we recently held our inaugural Sofinnova CEO Conference, which we co-hosted with Sofinnova Ventures of San Francisco from March 20-22. Our goal was to provide our CEOs with constructive and thought-provoking workshops, as well as the opportunity to network with an international peer group. The conference brought unique trans-Atlantic value to our portfolio companies.

The event was a real success. Despite the coinciding outbreak of war, 43 CEOs from Europe and the US flew to Corsica to attend the 2-day event. Special guests who addressed the group included information technology keynote Jean-Francois Pontal, CEO of European telecommunications giant Orange SA; life science keynote Jean-Pierre Garnier, CEO of GlaxoSmithKline; Ken Alwyn, a senior partner in PricewaterhouseCoopers’ global organization; and Marco Landi, former president of BMC Europe, former COO of Apple Computer and former president of Texas Instruments Europe.

The CEOs discussed their business challenges and shared best practices regarding critical business issues such as surviving in an adverse economic environment, development of a global strategy, strategic business plan development, optimal sales force management, development of a customer-focused organization, corporate governance, and, of course, “managing your board.”
We will host CEO conferences annually, alternating the locale between Europe and the U.S.


esmertec and Insignia collaborate to deliver Over-the-Air Repair™ capabilities for mobile terminals

Zurich, Switzerland, February 11, 2003 * * *
esmertec AG, the leading global supplier of embedded Java? virtual machines (JVMs) for the mobile world, and Insignia Solutions today announced an agreement whereby esmertec acquires the Insignia JVM related assets with the exception of Jeode Intellectual Property. esmertec will assume the entire JVM business through a final asset purchase in June 2004. esmertec and Insignia will also work together to proliferate Insignia’s Secure System Provisioning technology to esmertec’s customers and markets. Insignia Solutions is a market-share leading supplier of JVM software solutions for high-growth markets including mobile, digital TV, telematics and embedded systems and has partnerships with many key industry players. This acquisition strengthens and consolidates esmertec’s leadership position in providing Java solutions for mass market mobile and embedded devices. Combining the esmertec and Insignia customer bases as well as best-in-class compiling technologies provides the mobile industry with a best-of-breed solution.

” This acquisition makes perfect sense from a number of perspectives”, said Alain Blancquart, CEO of esmertec. “The combined R&D team will be the largest and most experienced in the industry, allowing us to continue to deliver world-class solutions to our partners and customers”. “In addition to this we will be able to extend esmertec’s market reach by building on the strong position that Insignia has in the PDA, industrial and automotive markets. I am truly delighted by this deal and am excited about the future”, he concluded. Commenting on the complimentary compiling technologies of the two companies, Hansruedi Heeb, esmertec’s President and CTO, said: “We are excited by the prospect of combining the brainpower of the two leading engineering teams in compiling J2ME CLDC solutions and we look forward to strengthening our leadership in the entire embedded Java space thanks to Insignia’s outstanding and proven technology”. With the sale of Insignia’s JVM business to esmertec, Insignia is refocusing on its highly successful Secure System Provisioning product line. The two companies have agreed to work together to deliver an end-to-end Over-the-Air Repair solution leveraging the complimentary strengths of the two companies. In addition, Insignia will gain a highly leverage entry into esmertec’s customer base and markets with this solution. “We are delighted to have reached an agreement with esmertec”, said Mark McMillan, President and COO of Insignia. “This acquisition makes esmertec the leading worldwide provider of mobile services enabling software in the industry and the infusion of cash to Insignia enables us to exclusively focus on the significant market opportunity for Secure System Provisioning – it’s a win-win situation for both companies”.

About esmertec
esmertec is the leading software company focusing on Java™ and mobile software technologies for handheld systems. Considered to be one of the most important players in the independent VM supplier space, its flagship product, Jbed™ ME, certified by Sun Microsystems, delivers high performance computing on small devices to service providers, mobile device manufacturers and application developers. Founded in 1999, esmertec is based in Switzerland with sales, engineering and support offices in the United States and Singapore and representation in Japan.

About Insignia Solutions
Insignia Solutions’ provisioning-infrastructure software enables wireless carriers and mobile device manufacturers to fully capitalize on the mobile service opportunity. Founded in 1986, Insignia is a market-share leading supplier of Java virtual machine software solutions for high-growth markets including mobile, digital TV, telematics, and embedded systems. More than 40 million units of Insignia’s JVM™ technology are licensed by major partners including Samsung, HP/Compaq, BSQUARE, Wind River, Fujitsu, NEC, Toshiba, Motorola and Siemens AG. Insignia Solutions is traded on NASDAQ under the symbol INSG. The company is headquartered in Fremont, California with R&D and European operations based in the United Kingdom, and its Asian HQ in Japan. For additional information about Insignia or its products please visit http://www.insignia.com/.

Visit website http://www.esmertec.com


Paris, 13 December 2002. Sofinnova Partners announces the departure of Franck Delorme, General Partner responsible for developing the Information Technology sector alongside Olivier Protard. This move will not change the firm’s investment strategy, which is to focus on two key sectors: Information Technology and Life Sciences. The hiring of Alain Rodermann, Partner, in 1999 and the additions to the IT team over the last two years of a new Partner, Jean Schmitt, and two new Investment Associates, gives Sofinnova Partners the means to continue developing this sector.

” After twelve years of operational and international management experience with Dassault Systèmes, I joined Sofinnova Partners as General Partner in 1995. I have been with the firm for eight years, which corresponds to two investment cycles in this business. I now want to capitalize on these two types of experience, and focus on operational management with a strong entrepreneurial outlook”, said Franck Delorme.

Olivier Protard added: “This is a natural career move for Franck and we wish him well. Furthermore, while this decision was motivated by personal projects, it was a mutual agreement, within the partnership spirit that guides the entire team”.

During his eight years with Sofinnova Partners, Franck Delorme made twelve investments in both software and networking/telecom companies. Examples are Activia Networks, MaxiMiles, Ortems, Sefas, Solsoft, Staff & Line and, more recently, CTS and 6Wind.

About Sofinnova Partners
Based in Paris since 1972, Sofinnova Partners is a leading independent French and European venture capital firm. With key operations in the information technology and life science sectors, its investment strategy is based on two principles: “Invest in projects with a high potential in their early stages of development” and “Act as lead or co-lead investor”. Its investment team comprises 13 investment partners who are all experts in their field and can assist companies in which Sofinnova chooses to invest. Sofinnova Partners has more than 500 million euros under management, a loyal base of international investors, and plans to strongly reinforce its European development in the coming years.


Ghent, Belgium, 25 September 2002 – Ablynx nv today announced that it has completed a 5 million euro venture financing round. Investors are GIMV (Belgium), Sofinnova Partners (France), and Gilde Investment Management (the Netherlands). The recently founded biopharmaceutical company will develop and commercialize a novel class of single-domain antibodies for health care applications, with a primary focus on therapeutics. Ablynx, headquartered in Ghent, is a spin-off of VIB (Flanders Interuniversity Institute for Biotechnology, Belgium) and VUB (Free University of Brussels, Belgium).

The “Ablynx antibodies” are derived from single-domain antibodies that naturally occur in certain animal species belonging to the Camelidae (camel, dromedary and llama), and that were initially discovered by researchers at the Free University of Brussels. Additional research conducted over the last few years by a multidisciplinary team within the Flanders Interuniversity Institute for Biotechnology (VIB), revealed that this novel class of antibodies exhibits some unique advantages over conventional multi-domain antibodies for use as pharmaceutical drugs. This extensive effort resulted in the creation of a broad knowledge base and an impressive intellectual property (IP) estate comprising over 40 patents and patent applications. Ablynx has obtained exclusive rights to this knowledge and IP for the field of human and animal health care, including proteomics applications.

Ablynx’ antibodies are engineered in such a way that they contain a single antigen-binding domain and are only one tenth the size of a conventional antibody. Because of their small size, they can penetrate more effectively into organs or tissues upon administration as therapeutic drugs. Moreover, Ablynx antibodies are able to bind to epitopes that are not (or only rarely) accessible to conventional antibodies, such as active site cavities in enzymes. They also bind with high specificity and affinity to a broad spectrum of potential disease targets and exhibit superior solubility and stability, even resisting the action of gut proteases. Their simple structure allows them to be efficiently produced through microbial fermentation, permitting cost-effective production on a large scale. Ablynx believes that these unique features will enable the Company to rapidly develop proprietary drugs with improved characteristics to compete effectively in the growing market of antibody-based therapeutics.

Dr. Mark Vaeck has recently joined Ablynx as Chief Executive Officer. Dr. Vaeck has worked in the biotechnology and pharmaceutical industry since 1983. Before joining Ablynx, he was Chief Operating Officer of Ceres Inc., a plant genomics company based in Malibu, California. Prior to that, he held senior management positions at Keygene, EuroCetus (Chiron Corp.), UCB Pharma, and Plant Genetic Systems. Dr. Vaeck received his Ph.D. in Immunology from the Free University of Brussels.


Ablynx’ first-round financing of EUR 5 million was provided by an international consortium of reputed venture capital companies with a known track record in biotech financing: GIMV-Biotech Fund Flanders (Belgium), Sofinnova Partners (France), and Gilde (the Netherlands). The Company is headquartered in Ghent and has research collaborations with VIB and VUB. Ablynx currently employs 10 people and intends to grow to about 50 within the next two years.

For more information about Ablynx:
Mark Vaeck, CEO, mark.vaeck@ablynx.com

Visit website http://www.ablynx.com


La société suisse Addex Pharmaceuticals annonce aujourd’hui la clôture d’un premier tour de table de 10 M€ (CHF 15.75 million ) mené conjointement par Index Ventures et Sofinnova Partners. Techno Venture Management, BCV Initiative Capital ainsi que des investisseurs individuels ont aussi participé à ce tour de financement. Richard Rimer, Partenaire chez Index Ventures et Antoine Papiernik, Partenaire Associé chez Sofinnova Partners, rejoignent le Conseil d’administration de la société aux côtés d’autres personnalités expérimentées du monde de l’industrie pharmaceutique et des biotechnologies.

Addex Pharmaceuticals (www.addexpharma.com) est une société de biopharmacie spécialisée dans la découverte, le développement et la mise sur le marché de nouveaux produits thérapeutiques pour le traitement des dépendances et d’autres états neuropsychiatriques. Addex Pharmaceuticals utilise une nouvelle approche scientifique intégrant les technologies moléculaires, behavioristes et chimiques afin de combattre la dépendance à la drogue. “La dépendance, qui fait partie des grandes questions de santé publique, représente un marché très étendu encore peu exploré. Addex Pharmaceuticals vise ce marché et plus particulièrement les dépendances à la nicotine, à l’alcool, à la cocaïne et aux opiacés”, souligne François Conquet, Président-directeur général d’Addex Pharmaceuticals. “Nous projetons aussi d’explorer d’autres indications telles que les processus de dépendance générée par l’anxiété et la dépression.”

L’équipe de recherche d’Addex Pharmaceuticals bénéficie à la fois d’une expertise dans le domaine de la dépendance et dans celui du développement pharmaceutique. Les membres de cette équipe se connaissent et travaillent ensemble depuis de nombreuses années. Il s’agit de scientifiques aux compétences complémentaires qui ont une connaissance en profondeur de l’industrie pharmaceutique. François Conquet en est le Président-directeur général, Mark Epping-Jordan, le Directeur Scientifique, Timothy Dyer, le Directeur Financier et Vincent Mutel, le Directeur de la Recherche et du Développement. George Koob, du Scripps Research Institute, Mark Geyer de l’Université de Californie (San Diego), Pierre Magistretti de l’Université de Lausanne, Barbara Mason de l’Université de Miami, et Charles Grudzinskas du CDDS (Université de Georgetown) font partie du Conseil Scientifique. “La valeur de cette équipe et son expertise tant industrielle que scientifique dans ce domaine bien spécifique, auront un impact certain sur le traitement de la dépendance,” commente Antoine Papiernik, Partenaire Associé chez Sofinnova Partners.

La plate-forme intégrée de découverte de médicaments développée par la société lui donne la possibilité d’identifier de nouvelles cibles et de découvrir des produits innovants pour le traitement de la dépendance. Parallèlement au développement de ses propres produits, Addex Pharmaceuticals a pour stratégie de prendre en licence des produits candidats à différents stades de leur développement, et notamment des produits en phase d’essais cliniques. “L’approche d’Addex Pharmaceuticals en termes de traitement de la dépendance est la seule à couvrir l’ensemble de la chaîne allant de la découverte scientifique au développement du produit et à sa mise sur le marché”, a déclaré Richard Rimer, Partenaire d’Index Ventures.

Les mécanismes de la dépendance à la drogue sont complexes : ils entraînent des altérations dans les processus naturels de la connaissance, de l’affect et des éléments vitaux constituant l’intégrité de l’espèce – la nourriture, l’eau, le sexe et l’instinct maternel -. Les médicaments visés devraient entraîner une réduction, voire une suppression de l’usage de la drogue, prévenir les rechutes chez les patients, atténuer leur état de manque et réduire l’impact pathologique et/ ou le taux de mortalité. La plupart des thérapies actuelles agissent sur les mêmes cibles que les drogues elles-même. Cependant, parce que ces cibles stimulent les quatre éléments vitaux précités, ainsi que des processus fondamentaux, comme l’activité motrice, leur modulation provoque fréquemment des effets secondaires significatifs. Contrairement aux thérapies existantes, la stratégie de développement d’Addex vise des cibles situées en amont du processus de dépendance et inhibe donc totalement cette dépendance. Les produits d’Addex Pharmaceuticals devraient donc s’appliquer à un plus grand nombre de dépendances, tout en évitant les effets secondaires habituellement observés. Cette approche pourrait également permettre le développement de médicaments efficaces pour le traitement d’autres indications psychiatriques.

A propos d’Addex Pharmaceuticals
Addex Pharmaceuticals (www.addexpharma.com) est une société de biopharmacie suisse qui utilise une nouvelle approche scientifique intégrant à la fois les technologies moléculaires, behavioristes et chimiques permettant de combattre la dépendance à la drogue et d’autres maladies neuropsychiatriques. Addex Pharmaceuticals s’appuie sur sa plate-forme intégrée de découverte de médicaments pour identifier de nouvelles cibles et développer des produits innovants pour le traitement de la dépendance. Parallèlement au développement de ses propres produits, Addex Pharmaceuticals cherche à prendre en licence des produits candidats à différents stades de développement, notamment des produits déjà en essais cliniques pour le traitement de la dépendance.

A propos d’Index Ventures
Index Ventures est une société de capital-risque européenne qui gère plus de 500 millions de dollars de fonds, spécialisée dans les hautes technologies et les sciences de la vie. Index, qui a initié ses investissements dans la technologie européenne en 1992, a financé plus de 40 sociétés au cours des dernières années. Index travaille en étroite collaboration avec les entrepreneurs afin de développer des sociétés capables de devenir des leaders dans leur domaine. Parmi les investisseurs d’Index Ventures, on compte plusieurs sociétés de technologie de premier plan ainsi que des investisseurs institutionnels. Index a en particulier investi dans des sociétés spécialisées dans les sciences de la vie, comme Genmab (Cotée au Neuer Markt: 565132.F, à Copenhagen: GEN.CO), Cellzome, 7TM Pharma, BioXell et ParAllele Bioscience. Pour plus d’informations : http://www.indexventures.com.

A propos de Sofinnova Partners
Basée à Paris depuis 1972, Sofinnova Partners est l’une des sociétés de capital-risque leaders en Europe, spécialisée dans le financement et l’accompagnement de jeunes sociétés européennes et américaines en forte croissance, dans les secteurs des technologies de l’information et des sciences de la vie. Sofinnova Partners gère au total plus de 500 M € de fonds. Dans les cinq dernières années, Sofinnova Partners a réalisé plus de 60 investissements, principalement en tant que chef de file. Dans le secteur des sciences de la vie, ces investissements se sont concentrés sur des sociétés de biopharmacie ou d’instrumentation médicale telles que Actelion, Nicox, Novuspharma, IDM et SpineVision.

Visit website http://www.addexpharma.com